TRPV1 promotes opioid analgesia during inflammation

 Abstract: Pain and inflammation are inherently linked responses to injury, infection, or chronic diseases. Given that acute inflammation in humans or mice enhances the analgesic properties of opioids, there is much interest in determining the inflammatory transducers that prime opioid receptor signaling in primary afferent nociceptors.

Continue reading

A Shot at Blocking Addiction

With the help of a NIH grant, University of New Mexico researchers are developing a vaccine that would block opioids from acting in the brain, a treatment that could play a key role in overcoming addiction. 

Continue reading
Topics:

Social Support Key to Remission from Suicidal Thoughts for Disabling Chronic Pain Sufferers

According to a new study, poverty and history of anxiety and depressive disorders were impediments to recovery from suicidal ideation. 

Continue reading

New Part D Opioid Overutilization Policies

CMS implemented new opioid policies for Medicare drug plans effective January 1, 2019. Medicare Part D enrollees who have not filled an opioid prescription recently (within the last 60 days) will be limited to up to a 7-...
Continue reading

AAPM35 On Demand Course Recordings Now Posted

Thank you to all of the faculty, attendees, and industry partners who contributed to the success of the AAPM 35th Annual Meeting & Preconferences held in Denver March 6-10, 2019. The following on demand courses that ...
Continue reading

AAPM Comments on AHRQ Key Questions for Systematic Review on Management of Primary Headaches in Pregnancy

Comments from the American Academy of Pain Medicine The American Academy of Pain Medicine thanks the Agency for the opportunity to comment on The Evidence-based Practice Center Program at the Agency for Healthcare Resear...
Continue reading

AAPM Foundation Convenes Opioid Reduction Consensus Panel

Pain management experts and patient advocates met this past week to begin developing clear evidence-informed guidance for healthcare clinicians on the reduction or elimination of opioids, when appropriate, for ...
Continue reading

FDA Identifies Harm Reported From Sudden Discontinuation of Opioid Pain Medicines

The U.S. Food and Drug Administration (FDA) has received reports of serious harm in patients who are physically dependent on opioid pain medicines suddenly having these medicines discontinued or the dose rapidly decreased. These include serious withdrawal symptoms, uncontrolled pain, psychological distress, and suicide. 

Continue reading
Topics:

2019-2020 AAPM Board of Directors Assumes Office

 AAPM is pleased to announce its 2019-2020 Board of Directors, who assumed office on Saturday, March 9, 2019.

Continue reading

Members Invited to Join AAPM Investigator Registry

Periodically AAPM is asked to provide names of possible research sites for industry-sponsored trials. If you are an AAPM member who is interested in being listed as a potential Principal Investigator and/or as a pot...
Continue reading